ECONOMIC EVALUATION OF DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Author(s)
Salazar A1, Guirant Corpi L2, Aguirre A2, Herrera M3, Chacon C4
1Janssen Mexico, Mexico City, IL, USA, 2Janssen Mexico, Mexico City, Mexico, 3Janssen, Mexico City, Mexico, 4Janssen LATAM, Mexico City, Mexico
Multiple myeloma (MM) is a disease characterized by clonal proliferation of plasma cells and for the presence of a paraprotein in serum, urine or both; its clinical manifestations are hypercalcemia, renal failure, anemia and osteolytic lesions. The prognosis of patients with MM is very variable, with a median survival of 2.5 to 3 years. OBJECTIVES: This analysis aims to develop a cost-effectiveness analysis of the use of daratumumab in patients with relapsed/refractory multiple myeloma (RRMM). METHODS: A cost-effectiveness analysis was developed to assess the use of daratumumab (DAR) as a combination therapy option for two different schemes of treatment: DAR+ lenalidomide+dexamethasone (DRd) and DAR+bortezomib+dexamethasone (DVd) for the treatment of patients with RRMM. Standard markov model for oncology was developed (progression free survival (PFS), overall survival and death). Comparators were carfilzomib (CAR) based-schemes: CAR+lenalidomide+dexamethasone (KRd) and CAR double dose+ dexamethasone (K2d), respectively. Only direct medical costs were included obtained from institutional sources and resource use was validated trough a Deplhi panel. Discount rates for health outcomes and costs used was 5%. Sensitivity analyses were performed to test the robustness of the model and base case results. Costs are expressed in 2017 USD ($1USD=$20MXN). RESULTS: Baseline analysis estimates that DRd and DVd were cost-effective schemes when compared with KRd and K2d with an incremental efficacy of 0.68 PFS life years (PFLYs) and 1.50 PFLYs, respectively. Robustness of the results were confirmed by deterministic and probabilistic sensitivity analysis. CONCLUSIONS: Daratumumab based-regimens overall generates better efficacy results with a good cost-effective profile compared to carfilzomib based regimens; hence daratumumab should be considered as a good alternative for patients with RRMM in the Mexican setting.
Conference/Value in Health Info
2018-05, ISPOR 2018, Baltimore, MD, USA
Value in Health, Vol. 21, S1 (May 2018)
Code
PSY56
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Multiple Diseases, Oncology, Systemic Disorders/Conditions